This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
 

The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response

Videoconference image
Rate:
 
Rating
 
20th Mar 201919:00 - 20:30

This promotional meeting is organised and fully funded by MSD. MSD products will be discussed at the meeting.

An exciting opportunity to hear the views of Professor Langer, an international scientific leader in NSCLC

OBJECTIVES:
  • To review the clinical rationale for the use of immunotherapy in first-line metastatic NSCLC
  • To discuss the importance of appropriate patient selection for different treatment strategies in first-line metastatic NSCLC, with the aim of improving survival and other important patient outcomes
  • To provide practical advice around the real-world use of immunotherapy in first-line metastatic NSCLC.
Click here for Prescribing Information.

Attend

Important For Online Events Only:

Click here to test the computer that you will be using to make sure you have the minimum technical requirements to attend this Webcast. Allow sufficient time before the Webcast for this test.

Agenda
Start timeDetails
19:00Welcome and Introductions
Dr Thomas Newsom-Davis
19:05The Importance of Immunotherapy in Treatment-Naïve, Metastatic NSCLC: Optimising Survival and Response
Dr Corey J. Langer
20:00Discussion and questions.
Dr Thomas Newsom-Davis
20:30Close
Speakers
Speaker image
Dr Thomas Newsom-Davis
Dr Thomas Newsom-Davis BSc MBBS FRCP PhD, Consultant in Medical Oncology, Chelsea and Westminster Hospital, London
Read more
Speaker image
Dr Corey J. Langer
Dr Corey J. Langer, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine.
Read more

GB-PDO-00111 Date of preparation: February 2019